Radiolabeled Imaging Probes Targeting Angiogenesis for Personalized Medicine

Author(s): Samantha Y. A. Terry, Mark Rijpkema, Keelara Abiraj, Winette T. van der Graaf, Wim J. Oyen, Otto C. Boerman

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 14 , 2014

Become EABM
Become Reviewer
Call for Editor


Angiogenesis is essential for tumor growth and inhibiting angiogenesis has become an important therapeutic strategy in clinical oncology. Nonetheless, the mechanisms behind anti-angiogenic therapeutics as well as resistance to these drugs remain unclear. With a lack of validated genetic or molecular biomarkers for anti-angiogenic responsiveness, novel methods to identify responsive patients are required. Non-invasive nuclear imaging would allow the elucidation of the basic drug mechanisms as well as resistance routes and aid the personalization of anti-angiogenic therapy by enabling target expression quantification prior to and during treatment. This review focuses on the development of radiolabeled probes to image four key proteins expressed during angiogenesis, namely vascular endothelial growth factor and its receptor, integrin αv β3, the extracellular domain of fibronectin and matrix metalloproteases, and how these probes can be utilized for personalized anti-angiogenic therapy.

Keywords: Angiogenesis, radiolabeled imaging probes, personalized medicine, integrin αv β3, VEGF, RGD.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 11 September, 2013
Page: [2293 - 2307]
Pages: 15
DOI: 10.2174/13816128113196660665
Price: $65

Article Metrics

PDF: 28